Emicizumab treatment: Impact on coagulation tests and biological monitoring of haemostasis according to clinical situations (BIMHO group proposals).
coagulation assay
emicizumab
haemophilia
Journal
European journal of haematology
ISSN: 1600-0609
Titre abrégé: Eur J Haematol
Pays: England
ID NLM: 8703985
Informations de publication
Date de publication:
Dec 2020
Dec 2020
Historique:
received:
10
06
2020
revised:
08
07
2020
accepted:
09
07
2020
pubmed:
16
7
2020
medline:
30
7
2021
entrez:
16
7
2020
Statut:
ppublish
Résumé
Emicizumab, a bispecific humanised monoclonal antibody restoring to some extent the function of activated FVIII deficient in haemophilia A, represents a major therapeutic advance in the management of haemophilia A patients. No dosage adjustment is required, which leads to a major change for patients used to regular biological monitoring which is particularly burdensome in the case of substitution therapy. In some circumstances, such as before an invasive procedure or in case of bleeding, biological monitoring will be necessary and emicizumab's interference with haemostasis tests, particularly those based on an activated partial thromboplastin times (aPTT), must be known to best interpret the tests and to select the most appropriate methods to guide therapy. The normalisation of aPTT in patients treated with emicizumab is not sufficient to consider haemostasis as normalised. In the event of administration of FVIII to a patient receiving emicizumab, the determination of FVIII should use a chromogenic method using non-human reagents. Coagulation global tests have been proposed to evaluate the biological response when using bypassing agents in patients treated with emicizumab, but the usefulness must be confirmed. The French group BIMHO presents proposals for biological monitoring of a patient treated with emicizumab according to clinical situations.
Substances chimiques
Antibodies, Bispecific
0
Antibodies, Monoclonal, Humanized
0
emicizumab
7NL2E3F6K3
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
675-681Informations de copyright
© 2020 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
Références
Haute Aurorité de Santé [Internet]. https://www.has-sante.fr/portail/jcms/c_2868847/fr/hemlibra-emicizumab-hemostatique. Accessed February 06, 2019.
Haute Autorité de Santé - HEMLIBRA [Internet]. [cited 2020 Apr 1]. Available from https://www.has-sante.fr/jcms/p_3114482/fr/hemlibra. Accessed April 1, 2020.
Oldenburg J, Mahlangu JN, Kim B, et al. Emicizumab prophylaxis in hemophilia A with inhibitors. N Engl J Med. 2017;377(9):809-818.
Pipe SW, Shima M, Lehle M, et al. Efficacy, safety, and pharmacokinetics of emicizumab prophylaxis given every 4 weeks in people with haemophilia A (HAVEN 4): a multicentre, open-label, non-randomised phase 3 study. Lancet Haematol. 2019;6(6):e295-e305.
Mahlangu J, Oldenburg J, Paz-Priel I, et al. Emicizumab prophylaxis in patients who have hemophilia A without inhibitors. N Engl J Med. 2018;379(9):811-822.
Rodriguez-Merchan EC, Valentino LA. Emicizumab: review of the literature and critical appraisal. Haemophilia. 2019;25(1):11-20.
Uchida N, Sambe T, Yoneyama K, et al. A first-in-human phase 1 study of ACE910, a novel factor VIII-mimetic bispecific antibody, in healthy subjects. Blood. 2016;127(13):1633-1641.
Paz-Priel I, Chang T, Asikanius E, et al. Immunogenicity of emicizumab in people with hemophilia A (PwHA): results from the HAVEN 1-4 studies. Blood. 2018;132(Supplement 1):633.
Susen S, Gruel Y, Godier A, et al. Management of bleeding and invasive procedures in haemophilia A patients with inhibitor treated with emicizumab (Hemlibra ® ): Proposals from the French network on inherited bleeding disorders (MHEMO), the French Reference Centre on Haemophilia, in collaboration with the French Working Group on Perioperative Haemostasis (GIHP). Haemophilia. 2019;25(5):731-737.
Hemlibra-epar-product-information_en.pdf [Internet]. [cited 2020 Apr 1]. Available from https://www.ema.europa.eu/en/documents/product-information/hemlibra-epar-product-information_en.pdf. Accessed April 1, 2020.
Adamkewicz JI, Chen DC, Paz-Priel I. Effects and interferences of emicizumab, a humanised bispecific antibody mimicking activated factor VIII cofactor function, on coagulation assays. Thromb Haemost. 2019;119(7):1084-1093.
Müller J, Pekrul I, Pötzsch B, Berning B, Oldenburg J, Spannagl M. Laboratory monitoring in emicizumab-treated persons with hemophilia A. Thromb Haemost. 2019;119(9):1384-1393.
Bowyer A, Kitchen S, Maclean R. Effects of emicizumab on APTT, one-stage and chromogenic assays of factor VIII in artificially spiked plasma and in samples from haemophilia A patients with inhibitors. Haemophilia. 2020;26(3):536-542.
Shima M, Hanabusa H, Taki M, et al. Factor VIII-mimetic function of humanized bispecific antibody in hemophilia A. N Engl J Med. 2016;374(21):2044-2053.
Nougier C, Jeanpierre E, Lasne D. Posters Abstracts - 2019 - Research and practice in thrombosis and haemostasis - Wiley Online Library [Internet]. 2019. [cited 2020 Apr 1]. Available from https://onlinelibrary.wiley.com/doi/pdf/10.1002/rth2.12229. Accessed April 1, 2020.
Bowyer AE, Lowe AE, Tiefenbacher S. Laboratory issues in gene therapy and emicizumab. Haemophilia [Internet]. 2020. May 29 [cited 2020 Jul 1]. Available from https://onlinelibrary.wiley.com/doi/abs/10.1111/hae.13976. Accessed July 1, 2020.
ECTH. 2018-ABSTRACT-book.pdf [Internet]. [cited 2020 Apr 1]. Available from http://ecth2018.org/wp-content/uploads/2018/09/ECTH-2018-ABSTRACT-book.pdf. Accessed April 1, 2020.
Hoffmann I, Jagdhuber F, Chen D, Davidson S, Richter N. Posters Abstracts - 2019 - Research and Practice in Thrombosis and Haemostasis - Wiley Online Library [Internet]. 2019. [cited 2020 Apr 1]. Available from https://onlinelibrary.wiley.com/doi/pdf/10.1002/rth2.12229. Accessed April 1, 2020.
Dargaud Y, Lienhart A, Janbain M, Le Quellec S, Enjolras N, Negrier C. Use of thrombin generation assay to personalize treatment of breakthrough bleeds in a patient with hemophilia and inhibitors receiving prophylaxis with emicizumab. Haematologica. 2018;103(4):e181-e183.
Santagostino E, Mancuso ME, Novembrino C, Solimeno LP, Tripodi A, Peyvandi F. Rescue FVIII replacement to secure haemostasis in a patient with haemophilia A and inhibitors on emicizumab prophylaxis undergoing hip replacement. Haematologica. 2019;2018:215129.
Kizilocak H, Yukhtman CL, Marquez-Casas E, Lee J, Donkin J, Young G. Management of perioperative hemostasis in a severe hemophilia A patient with inhibitors on emicizumab using global hemostasis assays. Ther Adv Hematol. 2019;10:2040620719860025.
Hartmann R, Feenstra T, Valentino L, Dockal M, Scheiflinger F. In vitro studies show synergistic effects of a procoagulant bispecific antibody and bypassing agents. J Thromb Haemost. 2018;16(8):1580-1591.
Furukawa S, Nogami K, Shimonishi N, Nakajima Y, Matsumoto T, Shima M. Prediction of the haemostatic effects of bypassing therapy using comprehensive coagulation assays in emicizumab prophylaxis-treated haemophilia A patients with inhibitors. Br J Haematol. 2020;1-9. https://doi.org/10.1111/bjh.16574
Yada K, Nogami K, Ogiwara K, et al. Global coagulation function assessed by rotational thromboelastometry predicts coagulation-steady state in individual hemophilia A patients receiving emicizumab prophylaxis. Int J Hematol. 2019;110(4):419-430.
Jenkins PV, Bowyer A, Burgess C, et al. Laboratory coagulation tests and emicizumab treatment A United Kingdom Haemophilia Centre Doctors' Organisation guideline. Haemophilia. 2020;26(1):151-155.
Lenting PJ, Denis CV, Christophe OD. Emicizumab, a bispecific antibody recognizing coagulation factors IX and X: how does it actually compare to factor VIII? Blood. 2017;130(23):2463-2468.
Druzgal CH, Kizilocak H, Brown J, Sennett M, Young G. Neutralizing antidrug antibody to emicizumab in a patient with severe hemophilia A with inhibitors: New case with detailed laboratory evaluation. J Thromb Haemost. 2020. [Epub ahead of print]
Adamkewicz JI, Kiialainen A, Paz-Priel I. Effects and interferences of emicizumab, a humanized bispecific antibody mimicking activated factor VIII cofactor function, on lupus anticoagulant assays. Int J Lab Hematol. 2020;42(2):e71-e75.